ARTICLE
23 December 2022

Health Canada Releases New Guidance Document On Clinical Evidence Requirements For Medical Devices

SB
Smart & Biggar
Contributor
Smart & Biggar is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montréal, Vancouver and Calgary. We are leaders in intellectual property and have been serving clients for over a century. Intellectual property rights are only valuable if they can be protected and exploited intelligently. At Smart & Biggar we are devoted to maximizing the value of our clients' intellectual property and technology assets. While we are proud that we have been selected repeatedly as Canada's leading intellectual property firm in numerous Canadian and international surveys, we recognize that our success is best measured by your success. Smart & Biggar operates as part of the IPH Limited group, under its own brand and independent from other IPH member firms. For more information, please visit https://www.smartbiggar.ca/
On November 15, 2022, Health Canada released a new guidance document, "Guidance on clinical evidence requirements for medical devices."
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On November 15, 2022, Health Canada released a new guidance document, "Guidance on clinical evidence requirements for medical devices." In this document, Health Canada provides guidance on clinical evidence requirements for Class II, III, and IV medical devices. This document does not apply to in vitro diagnostic devices (IVDDs).

The document includes guidance on when clinical data/evidence is required, methods to generate and evaluate clinical data, and how to compare devices appropriately. It also provides general principles and criteria for clinical evidence that supports amending licence applications, and additional obligations during the post-market phase.

Health Canada also released a companion document, "Examples of clinical evidence requirements for medical devices," which contains examples of different types of devices and outlines when clinical evidence is more likely or less likely to be required.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

ARTICLE
23 December 2022

Health Canada Releases New Guidance Document On Clinical Evidence Requirements For Medical Devices

Canada Food, Drugs, Healthcare, Life Sciences
Contributor
Smart & Biggar is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montréal, Vancouver and Calgary. We are leaders in intellectual property and have been serving clients for over a century. Intellectual property rights are only valuable if they can be protected and exploited intelligently. At Smart & Biggar we are devoted to maximizing the value of our clients' intellectual property and technology assets. While we are proud that we have been selected repeatedly as Canada's leading intellectual property firm in numerous Canadian and international surveys, we recognize that our success is best measured by your success. Smart & Biggar operates as part of the IPH Limited group, under its own brand and independent from other IPH member firms. For more information, please visit https://www.smartbiggar.ca/
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More